COMMUNIQUÉ DE PRESSE publié le 16/06/2025 à 09:20, il y a 1 année Alzchem Group AG: Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - 10th interim report Alzchem Group AG acquires 692 shares as part of a share buyback program. Detailed report available on company's website Share Buyback Stock Exchange Interim Report EU Regulation Alzchem Group AG
BRÈVE publiée le 23/05/2025 à 09:05, il y a 1 année Alzchem Group AG finalise sa planification de succession avec la nomination d'un nouveau directeur de l'exploitation Planification De La Relève Chef De L'exploitation Groupe Alzchem AG Produits Chimiques De Spécialité Dr Jürgen Sans
BRÈVE publiée le 23/05/2025 à 09:05, il y a 1 année Alzchem Group AG Finalizes Succession Planning with New COO Appointment Chief Operating Officer Succession Planning Alzchem Group AG Specialty Chemicals Dr. Jürgen Sans
COMMUNIQUÉ DE PRESSE publié le 23/05/2025 à 09:00, il y a 1 année Alzchem Group AG successfully completes long-term succession planning for its Management Board: Supervisory Board appoints Dr. Jürgen Sans as Chief Operating Officer with effect from 1 January 2026 Alzchem Group AG successfully completes long-term succession planning as Supervisory Board appoints Dr. Jürgen Sans as Chief Operating Officer from January 1, 2026 Chief Operating Officer Supervisory Board Succession Planning Alzchem Group AG Dr. Jürgen Sans
BRÈVE publiée le 09/05/2025 à 14:25, il y a 1 année 1 mois Alzchem Group AG augmente son dividende de 50 % et réélit son conseil de surveillance Exercice 2024 Conseil De Surveillance Valeur Actionnariale Assemblée Générale Annuelle Augmentation Des Dividendes
BRÈVE publiée le 09/05/2025 à 14:25, il y a 1 année 1 mois Alzchem Group AG Increases Dividend by 50% and Re-elects Supervisory Board Annual General Meeting Shareholder Value Supervisory Board Fiscal Year 2024 Dividend Increase
COMMUNIQUÉ DE PRESSE publié le 09/05/2025 à 14:20, il y a 1 année 1 mois Alzchem Group AG: Annual General Meeting approves 50% dividend increase to EUR 1.80 and re-election of Supervisory Board members Alzchem Group AG approves 50% dividend increase to EUR 1.80 at Annual General Meeting and re-elects Supervisory Board members. Successful fiscal year 2024 showcased Annual General Meeting Supervisory Board Fiscal Year 2024 Dividend Increase Alzchem Group AG
BRÈVE publiée le 30/04/2025 à 07:05, il y a 1 année 1 mois Alzchem Group AG Reports Continued Earnings Growth in Q1 2025 Alzchem Group AG EBITDA Growth Specialty Chemicals Q1 2025 Earnings Nitroguanidine Expansion
BRÈVE publiée le 30/04/2025 à 07:05, il y a 1 année 1 mois Alzchem Group AG annonce une croissance continue de ses bénéfices au premier trimestre 2025 Croissance De L'EBITDA Groupe Alzchem AG Produits Chimiques De Spécialité Résultats Du Premier Trimestre 2025 Expansion De La Nitroguanidine
COMMUNIQUÉ DE PRESSE publié le 30/04/2025 à 07:00, il y a 1 année 1 mois Alzchem Group AG continues earnings growth in the first quarter of 2025; projects to expand nitroguanidine capacity launched Alzchem Group AG achieves earnings growth in Q1 2025 despite lower revenue, plans to expand nitroguanidine capacity. Positive outlook for sales and EBITDA growth in 2025 Earnings Growth Sales Forecast Alzchem Group AG Q1 2025 Nitroguanidine Expansion
Publié le 22/06/2026 à 18:00, il y a 3 heures 40 minutes GUILLEMOT CORPORATION : DECES DE M. CLAUDE GUILLEMOT, Président du Groupe GUILLEMOT CORPORATION
Publié le 22/06/2026 à 21:05, il y a 35 minutes RUM Announces Voting Results From Annual General Meeting of Shareholders
Publié le 22/06/2026 à 19:45, il y a 1 heure 55 minutes Trans Canada Gold Appoints Paradigm Drilling Ltd. for Drilling at the Harrison Lake District Scale Gold Project, Drilling to Commence Shortly
Publié le 22/06/2026 à 15:58, il y a 5 heures 42 minutes Metallic Minerals Closes Upsized C$10.3 Million Bought Deal LIFE Private Placement
Publié le 22/06/2026 à 15:30, il y a 6 heures 10 minutes NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
Publié le 22/06/2026 à 15:00, il y a 6 heures 40 minutes Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Publié le 22/06/2026 à 21:07, il y a 32 minutes EQS-Adhoc: RWE Aktiengesellschaft: RWE sets placement price for shares from capital measure and raises gross proceeds of 4 billion EUR
Publié le 22/06/2026 à 20:50, il y a 49 minutes Ethlabs, Founded by Former Ethereum Foundation Contributors and Funded by Bitmine, Sharplink and Joe Lubin, Launches to Accelerate Ethereum's Institutional Supercycle
Publié le 22/06/2026 à 20:32, il y a 1 heure 7 minutes EQS-Adhoc: Deutsche Konsum Real Estate AG: Daniel Löhken appointed Chief Executive Officer of the Company and Dr Kai Gregor Klinger appointed new Chairman of the Supervisory Board
Publié le 22/06/2026 à 19:27, il y a 2 heures 13 minutes Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Publié le 22/06/2026 à 18:54, il y a 2 heures 45 minutes EQS-Adhoc: Brenntag SE publishes preliminary operating EBITDA for the second quarter of 2026 and increases its guidance for the financial year 2026